Myriad Pharmaceuticals, Inc.
320 Wakara Way
Salt Lake City,
UT 84108
United States - Map
Phone: 801-214-7800
Fax: 801-214-7992
Web Site: http://www.myriadpharma.com
| Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Its pipeline includes clinical and pre-clinical product candidates with mechanisms of action and novel chemical structures. The companys product candidates in clinical development include Azixa (MPC-6827), which is under Phase II clinical trial for the treatment of glioblastoma multiforme and metastatic melanoma; MPC-4326 for HIV-1 infection under Phase IIb clinical trial; and MPC-3100, a Phase I clinical trial product candidate for cancer treatment. Its products in preclinical programs comprise MPI-443803, an orally available, brain penetrant, microtubule destabilizing agent for the treatment of cancer; and MPI-461359, an orally available maturation inhibitor for the treatment of HIV-1 infection, as well as MPI-479605 for the treatment of cancer. The company also offers ProNet, a proprietary database of protein-protein interactions, which encompasses interactions between approximately 10 million protein fragments constructed from various organ tissues, including heart, brain, kidney, liver, breast, and prostate. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Adrian N. Hobden Ph.D., 56
Chief Exec. Officer, Pres |
$
821.00K |
$
9.80M | Mr. Robert J. Lollini , 55
Chief Financial Officer, Principal Accounting Officer and Treasurer |
$
105.00K |
$
0 | Mr. W. Wayne Laslie , 64
Chief Operating Officer and Chief Commercial Officer |
$
506.00K |
$
2.25M | Dr. Edward Swabb M.D, Ph.D, 61
Chief Medical Officer and Sr. VP of Drug Devel. |
$
361.00K |
$
1.70M | Ms. Barbara Berry , 58
Sr. VP of HR |
$
214.00K |
$
4.63M |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.14% Nasdaq 0.00%
Profile
